Clinical trial NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
Official title: A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: HER2-expressing Cancers
Keywords: JZP598
Lead sponsor: Jazz Pharmaceuticals
Sponsor class: INDUSTRY
Collaborators: name: ALX Oncology Inc.
First posted: 2021-08-30
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: single-arm, open-label, multi-cohort, multi-center study
Primary purpose: TREATMENT

Brief summary: This study is being done to find out if zanidatamab when given with evorpacept (ALX148) is safe and can treat patients with advanced (locally advanced \[inoperable\] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.

Detailed description: Part 1 of the study will first evaluate the safety and tolerability and establish the recommended doses (RDs) of zanidatamab in combination with evorpacept (ALX148). Part 2 of the study will evaluate the anti-tumor activity of the combination of zanidatamab plus evorpacept (ALX148) at the RD levels in indication-specific expansion cohorts.

Eligibility criteria: Inclusion Criteria:

* Locally advanced (inoperable) and/or metastatic HER2-expressing cancer based on local or central laboratory test results as follows:

  * Parts 1 and 2: HER2-positive breast cancer as defined per American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guidelines
  * Parts 1 and 2: HER2-low breast cancer (defined as immunohistochemistry \[IHC\] 1+ or IHC 2+; AND is currently not and has never been HER2-positive per the ASCO/CAP guidelines)
  * Part 2: HER2-positive gastroesophageal adenocarcinoma as defined per the ASCO/CAP gastric cancer-specific guidelines; or other HER2-overexpressing non-breast cancers (defined as IHC 3+; or IHC 2+ and in situ hybridization \[ISH\]+) per the ASCO/CAP guidelines for breast cancer
* Progression after or during the most recent systemic regimen of treatment for advanced cancer. For both Part 1 and Part 2, prior therapies must have included approved agents known to confer clinical benefit.

  * Subjects with HER2-positive breast cancer who did not receive trastuzumab or pertuzumab due to medical contraindications will not be eligible for this study
  * Subjects with HER2-low breast cancer who have received prior HER2-targeted therapy (other than trastuzumab deruxtecan, which is allowed but not required) will not be eligible for this study
* Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
* Willingness to undergo a new biopsy to provide a tumor tissue for central laboratory testing of HER2 protein expression and gene amplification by IHC and ISH assays, respectively
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Adequate organ functions
* Adequate cardiac left ventricular function, as defined by a left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA) obtained within 4 weeks prior to first dose of study treatment

Exclusion Criteria:

* Previous allogeneic stem cell transplant
* Prior treatment with any anti-CD47 or anti-signal regulatory protein alpha (SIRPα) agent
* Prior or concurrent invasive malignancy whose natural history or treatment has, in the opinion of the investigator or medical monitor, the potential to interfere with the safety or efficacy assessment of the investigational regimen
* Received systemic anticancer therapy within 4 weeks of starting study treatment (6 weeks for mitomycin C or nitrosoureas). Received radiotherapy within 2 weeks of the first dose of zanidatamab/evorpacept (ALX148)
* Untreated brain metastases, symptomatic brain metastases; or radiation treatment (stereotactic radiosurgery and whole brain radiation) for brain metastases within 2 weeks of start of study treatment
* Known leptomeningeal disease
* Active hepatitis
* Infection with human immunodeficiency virus (HIV)-1 or HIV-2. (Exception: Subjects with well controlled HIV \[e.g., CD4 \> 350/mm3 and undetectable viral load\] are eligible.)
* QTc Fridericia (QTcF) \> 470 ms
* History of myocardial infarction or unstable angina within 6 months prior to enrollment, troponin levels consistent with myocardial infarction, or clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension, or any history of symptomatic congestive heart failure
* Acute or chronic uncontrolled pancreatitis or Child-Pugh Class C liver disease

Primary outcomes:
measure: Incidence of dose-limiting toxicities (DLTs; Part 1)
timeFrame: Up to 4 weeks
measure: Incidence of AEs (Part 1)
timeFrame: Up to 7 months
measure: Incidence of clinical laboratory abnormalities (Part 1)
timeFrame: Up to 7 months
measure: Confirmed objective response rate (ORR)(Part 2)
timeFrame: Up to 2 years
Secondary outcomes:
measure: Disease control rate (DCR)(Part 2)
timeFrame: Up to 2 years
measure: Clinical benefit rate (CBR)(Part 2)
timeFrame: Up to 2 years
measure: Duration of response (DOR)(Part 2)
timeFrame: Up to 2 years
measure: Progression-free survival (PFS)(Part 2)
timeFrame: Up to 2 years
measure: Progression-free survival 6 (PFS6)(Part 2)
timeFrame: Up to 6 months
measure: Overall survival (OS)(Part 2)
timeFrame: Up to 2 years
measure: Incidence of AEs (Part 2)
timeFrame: Up to 7 months
measure: Incidence of clinical laboratory abnormalities (Part 2)
timeFrame: Up to 7 months
measure: Maximum serum concentration of zanidatamab and evorpacept (ALX148) (Part 2)
timeFrame: Up to 7 months
measure: Trough concentration of zanidatamab and evorpacept (ALX148) (Part 2)
timeFrame: Up to 7 months
measure: Incidence of anti-drug antibodies (ADAs)(Part 2)
timeFrame: Up to 7 months
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: UC San Diego - Moores Cancer Center
state: California
city: Los Angeles
country: United States
facility: UCLA Department of Medicine Hematology/Oncology
state: California
city: Orange
country: United States
facility: UC Irvine Health - Chao Family Comprehensive Cancer Center
state: California
city: Sarasota
country: United States
facility: Florida Cancer Specialists
state: Florida
city: East Brunswick
country: United States
facility: Astera Cancer Care
state: New Jersey
city: Cleveland
country: United States
facility: University Hospitals Cleveland Medical Center
state: Ohio
city: Pittsburgh
country: United States
facility: Magee-Womens Hospital of UPMC
state: Pennsylvania
city: Houston
country: United States
facility: The University of Texas MD Anderson Cancer Center
state: Texas
city: Burlington
country: United States
facility: University of Vermont Medical Center
state: Vermont
city: Tacoma
country: United States
facility: Northwest Medical Specialties, PLLC
state: Washington
city: Madison
country: United States
facility: University of Wisconsin - Madison
state: Wisconsin
Study officials:
References: